Evidence map›Paper›PMID 35106961›Full record

Trial reportAnnals of clinical and translational neurology2022

Sustained immunotolerance in multiple sclerosis after stem cell transplant.

Malini Visweswaran, Kevin Hendrawan, Jennifer C Massey, Melissa L Khoo, Carole D Ford, John J Zaunders, Barbara Withers, Ian J Sutton, David D F Ma, John J Moore

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Natural killer cells in the central nervous system.Cell communication and signaling : CCS · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Malini VisweswaranBlood, Stem Cells and Cancer Research Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.ORCID 0000-0003-1200-0131
Kevin HendrawanBlood, Stem Cells and Cancer Research Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
Jennifer C MasseyBlood, Stem Cells and Cancer Research Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
Melissa L KhooBlood, Stem Cells and Cancer Research Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
Carole D FordBlood, Stem Cells and Cancer Research Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
John J ZaundersNSW State Reference Laboratory for HIV, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
Barbara WithersBlood, Stem Cells and Cancer Research Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
Ian J SuttonDepartment of Neurology, St Vincent's Hospital Sydney, Darlinghurst, Sydney, New South Wales, Australia.
David D F MaBlood, Stem Cells and Cancer Research Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
John J MooreBlood, Stem Cells and Cancer Research Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
UNSW Sydney · AUSt Vincent's Hospital Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAutologous haematopoietic stem cell transplantation (AHSCT) has the potential to induce sustained periods of disease remission in multiple sclerosis (MS), which is an inflammatory disease of the central nervous system (CNS) characterised by demyelination and axonal degeneration. However, the mechanisms associated with durable treatment responses in MS require further elucidation.

methodsTo characterise the longer term immune reconstitution effects of AHSCT at 24 and 36 months (M) post-transplant, high-dimensional immunophenotyping of peripheral blood mononuclear cells from 22 MS patients was performed using two custom-designed 18-colour flow cytometry panels.

resultsThe higher baseline frequencies of specific pro-inflammatory immune cells (T-helper-17 (Th17) cells, mucosal-associated invariant T-cells and CNS-homing T-conventional (T-conv) cells observed in MS patients were decreased post-AHSCT by 36M. This was accompanied by a post-AHSCT increase in frequencies and absolute counts of immunoregulatory CD56

interpretationAHSCT induces substantial recalibration of pro-inflammatory and immunoregulatory components of the immune system of MS patients for up to 36M post-transplant.

Indexed as

Hematopoietic Stem Cell TransplantationLeukocytes, MononuclearAdultFemaleFollow-Up StudiesHumansMaleMiddle AgedMultiple SclerosisOutcome Assessment, Health CareYoung Adult

Identifiers

PMID35106961
PMCPMC8862434
OpenAlexW4210369022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.